Compare RBOT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBOT | ANVS |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 111.3M |
| IPO Year | N/A | 2020 |
| Metric | RBOT | ANVS |
|---|---|---|
| Price | $2.59 | $4.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $13.50 |
| AVG Volume (30 Days) | 137.8K | ★ 606.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.11 |
| 52 Week High | $18.97 | $5.57 |
| Indicator | RBOT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 57.45 |
| Support Level | $1.81 | $3.26 |
| Resistance Level | $2.76 | $3.72 |
| Average True Range (ATR) | 0.24 | 0.26 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 79.06 | 90.99 |
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.